Summary of Use during Lactation

No information is available on the clinical use of talazoparib during breastfeeding. Because talazoparib is 74% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during talazoparib therapy and for one month after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Name

Talazoparib

CAS Registry Number

1207456-01-6

Drug Class

• Breast Feeding
• Lactation
• Antineoplastic Agents
• Enzyme Inhibitors
• Signal Transduction Inhibitors
• PARP Inhibitors